Drug Profile

Cannabinoid controlled release - InnoCan Pharma

Alternative Names: Cannabinoid loaded liposomes - Innocan Pharma ; LPT-CBD

Latest Information Update: 23 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hebrew University of Jerusalem
Class Analgesics; Antiepileptic drugs; Cannabinoids
Mechanism of Action Cannabinoid receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Epilepsy; Pain

Most Recent Events

15 Oct 2025 InnoCan Pharma receives patent allowance for Cannabinoid controlled release in Japan
06 May 2025 InnoCan Pharma receives notice of allowance for patent covering its proprietary topical pain-relief technology in Mexico
07 Apr 2025 InnoCan Pharma files for patent protection for liposome-based CBD technology in China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com